Results 91 to 100 of about 400,631 (298)

Inflammation Unchecked: Concurrent Kawasaki Disease and Stevens‐Johnson Syndrome in an 18‐Month‐Old Child

open access: yes
Arthritis Care &Research, EarlyView.
Catherine Deffendall   +6 more
wiley   +1 more source

Engineering Antigen Density on M13 Bacteriophage for Personalized Nanovaccine

open access: yesAdvanced Healthcare Materials, EarlyView.
Increasing antigen density on the phage capsid impacts phage uptake and antigen cross‐presentation by antigen‐presenting cells, leading to enhanced activation of antitumor CD8+ T cells in the draining lymph nodes. These activated CD8+ T cells subsequently recognize the antigen‐expressing tumors and mediate their specific cytotoxic killing, thereby ...
Shengnan Huang   +7 more
wiley   +1 more source

Atom‐Efficient Cerium‐Based Molecular Cages as Biocompatible Reactive Oxygen Scavengers

open access: yesAdvanced Healthcare Materials, EarlyView.
Discrete mixed‐valent cerium molecular cages organize accessible redox centers within confined coordination environments and scavenge superoxide, hydrogen peroxide, and hydroxyl radicals. Encapsulation of the lead cage in an ROS‐responsive DTP nanoplatform enables lesion‐associated delivery, attenuates macrophage oxidative stress and inflammation, and ...
Chao Li   +9 more
wiley   +1 more source

Pharmacokinetic results summary.

open access: yes, 2018
Pharmacokinetic results summary.
Ruth F. Dumpit (5328644)   +11 more
core   +1 more source

Pressure‐Assisted Drug Delivery Using High‐Pressure Balloon Platform Improves Vascular Drug Penetration and Anti‐Restenotic Effects

open access: yesAdvanced Healthcare Materials, EarlyView.
A dual‐layer high‐pressure drug‐coated balloon (HP@DCB) increased balloon‐wall contact and promoted deeper paclitaxel (PTX) penetration than a conventional noncompliant DCB. In in vivo study, HP@DCB treatment improved luminal patency and reduced neointimal hyperplasia, supporting pressure‐assisted drug delivery as a promising strategy for enhancing the
Seung Jin Eo   +10 more
wiley   +1 more source

Establishing a physiologically based pharmacokinetic framework for aldehyde oxidase and dual aldehyde oxidase‐CYP substrates

open access: yesCPT: Pharmacometrics & Systems Pharmacology
Aldehyde oxidase (AO) contributes to the clearance of many approved and investigational small molecule drugs, which are often dual substrates of AO and drug‐metabolizing enzymes such as cytochrome P450s (CYPs).
Nihan Izat   +15 more
doaj   +1 more source

Dual‐Mechanism Suppression of Posterior Capsule Opacification by an MMP2/9‐Responsive Sulforaphane‐Eluting Intraocular Lens

open access: yesAdvanced Healthcare Materials, EarlyView.
An MMP‐responsive, sulforaphane‐eluting intraocular lens (GelMA‐SFN@IOL) is developed to prevent posterior capsule opacification. Pathological MMP‐2/9 triggers sulforaphane release; sulforaphane enhances autophagy and downregulates MMP‐2/9, while suppressing epithelial‐mesenchymal transition.
Ying‐Yan Mao   +9 more
wiley   +1 more source

Pharmacokinetic parameters calculated.

open access: yes, 2018
Pharmacokinetic parameters calculated.
Geert J. Behets (630682)   +10 more
core   +1 more source

Charge‐Reversed Lipid Nanoparticles Enable Encapsulation of Pt2L4 Nanocages for In vivo Anti‐Cancer Treatment

open access: yesAdvanced Materials, EarlyView.
Charge‐reversed lipid nanoparticles (revLNPs) enable efficient encapsulation and delivery of cationic Pt2L4 nanocages. Encapsulation preserves potent anticancer activity while improving circulation, reducing vascular leakage, and promoting favorable biodistribution in vivo.
Renzo A. Knol   +16 more
wiley   +1 more source

A Systematic Review of Complement-Targeting Therapies for Geographic Atrophy: Insights into Advanced Drug Delivery Systems and Gene-Based Approaches

open access: yesPharmaceutics
Background/Objectives: Geographic atrophy (GA), an advanced form of dry age-related macular degeneration (AMD), causes irreversible central vision loss and has limited treatment options.
Paula Fernández-Muro   +3 more
doaj   +1 more source

Home - About - Disclaimer - Privacy